Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease

Texas Alzheimer's Disease Research and Care Consortium

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Abstract

Introduction: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and homocysteine (Hcy) have been linked to inflammation and Alzheimer's disease (AD). Using a case-control design, we examined their independent effects and interactions with cardiovascular disease equivalent (CVDE), on AD risk. Methods: AD cases and controls were from the Texas Alzheimer's Research and Care Consortium study. Lp-PLA2 was determined using the PLAC test (diaDexus, Inc), and Hcy by recombinant cycling assay (Roche Hitachi 911). Logistic regression was used to predict AD case status. We assayed for Lp-PLA2 in the brain tissue of cases and controls. Results: AD case status was independently associated with Lp-PLA2 and Hcy above the median (odds ratio [OR] = 1.91; 95% confidence interval [CI] = 1.22-2.97; P <.001 and OR = 1.81; 95% CI = 1.16-2.82; P =.009, respectively). Lp-PLA2, but not Hcy, interacted with CVDE to increase risk. Lp-PLA2 was absent from the brain tissue in both groups. Discussion: Higher Lp-PLA2 and Hcy are independently associated with AD. The association of Lp-PLA2 with AD may be mediated through vascular damage.

Original languageEnglish
Pages (from-to)464-471
Number of pages8
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume1
Issue number4
DOIs
StatePublished - 1 Dec 2015

Fingerprint

1-Alkyl-2-acetylglycerophosphocholine Esterase
Homocysteine
Alzheimer Disease
Cardiovascular Diseases
Odds Ratio
Confidence Intervals
Brain
Blood Vessels
Logistic Models
Inflammation

Keywords

  • Alzheimer's disease
  • Biomarkers
  • Dementia
  • Homocysteine
  • Lp-PLA2

Cite this

Texas Alzheimer's Disease Research and Care Consortium. / Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease. In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2015 ; Vol. 1, No. 4. pp. 464-471.
@article{a10a988393db4f099063dff755ba925c,
title = "Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease",
abstract = "Introduction: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and homocysteine (Hcy) have been linked to inflammation and Alzheimer's disease (AD). Using a case-control design, we examined their independent effects and interactions with cardiovascular disease equivalent (CVDE), on AD risk. Methods: AD cases and controls were from the Texas Alzheimer's Research and Care Consortium study. Lp-PLA2 was determined using the PLAC test (diaDexus, Inc), and Hcy by recombinant cycling assay (Roche Hitachi 911). Logistic regression was used to predict AD case status. We assayed for Lp-PLA2 in the brain tissue of cases and controls. Results: AD case status was independently associated with Lp-PLA2 and Hcy above the median (odds ratio [OR] = 1.91; 95{\%} confidence interval [CI] = 1.22-2.97; P <.001 and OR = 1.81; 95{\%} CI = 1.16-2.82; P =.009, respectively). Lp-PLA2, but not Hcy, interacted with CVDE to increase risk. Lp-PLA2 was absent from the brain tissue in both groups. Discussion: Higher Lp-PLA2 and Hcy are independently associated with AD. The association of Lp-PLA2 with AD may be mediated through vascular damage.",
keywords = "Alzheimer's disease, Biomarkers, Dementia, Homocysteine, Lp-PLA2",
author = "{Texas Alzheimer's Disease Research and Care Consortium} and Doody, {Rachelle S.} and Jasenka Demirovic and Ballantyne, {Christie M.} and Wenyaw Chan and Barber, {Robert Clinton} and Suzanne Powell and Valory Pavlik and Susan Rountree and Paul Massman and Eveleen Darby and Tracy Evans and Aisha Khaleeq and Gregory Schrimsher and Andrew Dentino and Ronnie Orozco and Fairchild, {Thomas J.} and Janice Knebl and Sidney O'Bryant and James Hall and Douglas Mains and Lisa Alvarez and Erin Braddock and Rosemary McCallum and Johnson, {Leigh A.} and Perrie Adams and Roger Rosenberg and Myron Weiner and Benjamin Williams and Quiceno, {Mary Ellen} and Quiceno, {Mary Ellen} and Quiceno, {Mary Ellen} and Guanghua Xiao and Doris Svetlik and Amy Werry and Janet Smith and Donald Royall and Raymond Palmer and Marsha Polk",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.dadm.2015.08.001",
language = "English",
volume = "1",
pages = "464--471",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",
number = "4",

}

Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease. / Texas Alzheimer's Disease Research and Care Consortium.

In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 1, No. 4, 01.12.2015, p. 464-471.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease

AU - Texas Alzheimer's Disease Research and Care Consortium

AU - Doody, Rachelle S.

AU - Demirovic, Jasenka

AU - Ballantyne, Christie M.

AU - Chan, Wenyaw

AU - Barber, Robert Clinton

AU - Powell, Suzanne

AU - Pavlik, Valory

AU - Rountree, Susan

AU - Massman, Paul

AU - Darby, Eveleen

AU - Evans, Tracy

AU - Khaleeq, Aisha

AU - Schrimsher, Gregory

AU - Dentino, Andrew

AU - Orozco, Ronnie

AU - Fairchild, Thomas J.

AU - Knebl, Janice

AU - O'Bryant, Sidney

AU - Hall, James

AU - Mains, Douglas

AU - Alvarez, Lisa

AU - Braddock, Erin

AU - McCallum, Rosemary

AU - Johnson, Leigh A.

AU - Adams, Perrie

AU - Rosenberg, Roger

AU - Weiner, Myron

AU - Williams, Benjamin

AU - Quiceno, Mary Ellen

AU - Quiceno, Mary Ellen

AU - Quiceno, Mary Ellen

AU - Xiao, Guanghua

AU - Svetlik, Doris

AU - Werry, Amy

AU - Smith, Janet

AU - Royall, Donald

AU - Palmer, Raymond

AU - Polk, Marsha

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Introduction: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and homocysteine (Hcy) have been linked to inflammation and Alzheimer's disease (AD). Using a case-control design, we examined their independent effects and interactions with cardiovascular disease equivalent (CVDE), on AD risk. Methods: AD cases and controls were from the Texas Alzheimer's Research and Care Consortium study. Lp-PLA2 was determined using the PLAC test (diaDexus, Inc), and Hcy by recombinant cycling assay (Roche Hitachi 911). Logistic regression was used to predict AD case status. We assayed for Lp-PLA2 in the brain tissue of cases and controls. Results: AD case status was independently associated with Lp-PLA2 and Hcy above the median (odds ratio [OR] = 1.91; 95% confidence interval [CI] = 1.22-2.97; P <.001 and OR = 1.81; 95% CI = 1.16-2.82; P =.009, respectively). Lp-PLA2, but not Hcy, interacted with CVDE to increase risk. Lp-PLA2 was absent from the brain tissue in both groups. Discussion: Higher Lp-PLA2 and Hcy are independently associated with AD. The association of Lp-PLA2 with AD may be mediated through vascular damage.

AB - Introduction: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and homocysteine (Hcy) have been linked to inflammation and Alzheimer's disease (AD). Using a case-control design, we examined their independent effects and interactions with cardiovascular disease equivalent (CVDE), on AD risk. Methods: AD cases and controls were from the Texas Alzheimer's Research and Care Consortium study. Lp-PLA2 was determined using the PLAC test (diaDexus, Inc), and Hcy by recombinant cycling assay (Roche Hitachi 911). Logistic regression was used to predict AD case status. We assayed for Lp-PLA2 in the brain tissue of cases and controls. Results: AD case status was independently associated with Lp-PLA2 and Hcy above the median (odds ratio [OR] = 1.91; 95% confidence interval [CI] = 1.22-2.97; P <.001 and OR = 1.81; 95% CI = 1.16-2.82; P =.009, respectively). Lp-PLA2, but not Hcy, interacted with CVDE to increase risk. Lp-PLA2 was absent from the brain tissue in both groups. Discussion: Higher Lp-PLA2 and Hcy are independently associated with AD. The association of Lp-PLA2 with AD may be mediated through vascular damage.

KW - Alzheimer's disease

KW - Biomarkers

KW - Dementia

KW - Homocysteine

KW - Lp-PLA2

UR - http://www.scopus.com/inward/record.url?scp=84949563915&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2015.08.001

DO - 10.1016/j.dadm.2015.08.001

M3 - Article

VL - 1

SP - 464

EP - 471

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

SN - 2352-8729

IS - 4

ER -